Oncosil Medical Ltd
ASX:OSL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Oncosil Medical Ltd
ASX:OSL
|
AU |
|
Red Rock Resorts Inc
NASDAQ:RRR
|
US |
|
Swissquote Group Holding SA
SIX:SQN
|
CH |
|
R
|
Ravad Ltd
TASE:RAVD
|
IL |
|
W
|
Wooshin Systems Co Ltd
KRX:017370
|
KR |
|
SORIL Infra Resources Ltd
NSE:SORILINFRA
|
IN |
|
Fibra Uno Administracion SA de CV
BMV:FUNO11
|
MX |
|
O
|
Ock Group Bhd
KLSE:OCK
|
MY |
|
N
|
NHN KCP Corp
KOSDAQ:060250
|
KR |
|
Graco Inc
NYSE:GGG
|
US |
|
C
|
China Shenhua Energy Co Ltd
OTC:CSUAY
|
CN |
|
TKC Corp
TSE:9746
|
JP |
|
Corporacion Moctezuma SAB de CV
BMV:CMOCTEZ
|
MX |
|
SFL Corporation Ltd
NYSE:SFL
|
BM |
|
L
|
Lottomatica Group SpA
MIL:LTMC
|
IT |
|
Mullen Automotive Inc
NASDAQ:BINI
|
US |
|
Valeo Pharma Inc
TSX:VPH
|
CA |
|
Pnb Gilts Ltd
NSE:PNBGILTS
|
IN |
|
A
|
Anhui Guangxin Agrochemical Co Ltd
SSE:603599
|
CN |
|
S
|
Structure Therapeutics Inc
NASDAQ:GPCR
|
US |
Oncosil Medical Ltd
OncoSil Medical Ltd. develops and commercializes neurology services, including those for pancreatic cancer. The company is headquartered in North Sydney, New South Wales. The company went IPO on 2005-08-15. The firm is focused on unresectable locally advanced pancreatic cancer (LAPC). The firm's lead product, OncoSil, is a single-use brachytherapy internal radiation device used to deliver a pre-determined dose of beta radiation directly into cancerous tissue. The OncoSil consists of microparticles that contain a radioisotope phosphorous-32 and a formulated diluent, which acts as a carrier to facilitate the implantation of the microparticles into the target tissue. The company enables doctors to target a greater radiation dose directly to the tumor, while sparing surrounding critical organs. The OncoSil device is used for the treatment of unresectable LAPC and is used in conjunction with chemotherapy.
OncoSil Medical Ltd. develops and commercializes neurology services, including those for pancreatic cancer. The company is headquartered in North Sydney, New South Wales. The company went IPO on 2005-08-15. The firm is focused on unresectable locally advanced pancreatic cancer (LAPC). The firm's lead product, OncoSil, is a single-use brachytherapy internal radiation device used to deliver a pre-determined dose of beta radiation directly into cancerous tissue. The OncoSil consists of microparticles that contain a radioisotope phosphorous-32 and a formulated diluent, which acts as a carrier to facilitate the implantation of the microparticles into the target tissue. The company enables doctors to target a greater radiation dose directly to the tumor, while sparing surrounding critical organs. The OncoSil device is used for the treatment of unresectable LAPC and is used in conjunction with chemotherapy.
